Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-33912
Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
Müller2021_Article_InfluencesOnPathologicComplete.pdf739,62 kBAdobe PDFÖffnen/Anzeigen
Titel: Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
VerfasserIn: Müller, Carolin
Schmidt, Gilda
Juhasz-Böss, Ingolf
Jung, Lisa
Huwer, Sarah
Solomayer, Erich-Franz
Juhasz-Böss, Stephanie
Sprache: Englisch
In:
Titel: Archives of Gynecology and Obstetrics
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2021
Freie Schlagwörter: Breast cancer
Neo-adjuvant therapy
Pathologic complete response
Clinical trials
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Purpose Pathologic complete response is associated with longer disease-free survival and better overall survival after neoadjuvant chemotherapy in breast cancer patients. We, therefore, evaluated factors influencing pathologic complete response. Methods Patients receiving neoadjuvant chemotherapy from 2015 to 2018 at the Saarland University Hospital were included. Patients’ age, tumor stage, tumor biology, genetic mutation, recurrent cancer, discontinuation of chemotherapy, and participation in clinical trials were extracted from electronic medical records. Binary logistic regression was performed to evaluate the influence of these factors on pathologic complete response. Results Data of 183 patients were included. The median patient’s age was 54 years (22–78). The median interval between diagnosis and onset of chemotherapy was 28 days (14–91); between end of chemotherapy and surgery 28 days (9–57). Sixty-two patients (34%) participated in clinical trials for chemotherapy. A total of 86 patients (47%) achieved pathologic complete response. Patient’s age, genetic mutation, recurrent cancers, or discontinuation of chemotherapy (due to side effects) and time intervals (between diagnosis and onset of chemotherapy, as well as between end of chemotherapy and surgery) did not influence pathologic complete response. Patients with high Ki67, high grading, Her2 positive tumors, as well as patients participating in clinical trials for chemotherapy had a higher chance of having pathologic complete response. Patients with Luminal B tumors had a lower chance for pathologic complete response. Conclusion Particularly patients with high risk cancer and patients, participating in clinical trials benefit most from chemotherapy. Therefore, breast cancer patients can be encouraged to participate in clinical trials for chemotherapy.
DOI der Erstveröffentlichung: 10.1007/s00404-021-06018-6
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-339128
hdl:20.500.11880/31215
http://dx.doi.org/10.22028/D291-33912
ISSN: 1432-0711
0932-0067
Datum des Eintrags: 23-Apr-2021
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Frauenheilkunde
Professur: M - Prof. Dr. E.-F. Solomayer
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons